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 Introduction 
 Annually there are 9.4 million deaths worldwide attributed 
to hypertension, which remains the largest contributor to 
the global burden of disease and mortality. 1 Hypertension is 
common, affecting one third of adults over the age of 18 years, 
with a projected increase in prevalence due to the growing 
population and ageing society. Despite increasing awareness 
and access to a number of antihypertensive drug classes, 
of those on treatment for hypertension only 30–40% are 
controlled to current target. Controlling blood pressure (BP) 
with antihypertensive drugs is one of the most cost-effective 
methods of reducing premature cardiovascular morbidity and 
mortality. 2 
 The International Society of Hypertension (ISH), supported 
by the World Hypertension League and national societies, 
deemed May 2017 May Measurement Month (MMM). The 
ambitious goal of MMM was to screen 25 million people 
globally to highlight the need for increased BP screening, 
to identify and reduce the BPs of people found to have 
hypertension. 
 On the eve of World Hypertension Day 2017, the Royal College 
of Physicians (RCP) and the British and Irish Hypertension 
Society (BIHS) held the ‘Hypertension – state of the Art 2017’ 
conference bringing together a wealth of expert speakers to 
provide an update on recent advances in the understanding and 
management of hypertension. 
 New evidence in 2017: how will it change practice? 
 The optimum fourth-line antihypertensive agent was 
investigated in the PATHWAY-2 study with spironolactone 
emerging as the most effective agent compared with bisoprolol, 
doxazosin and placebo. 3 
 Single pill combinations (SPCs) have been shown to be 
quicker and more effective in controlling BP than monotherapy 
or the combination of two single drugs with reduced side 
effects, improved patient adherence, improved cardiovascular 
protection and associated cost savings. 
 Worldwide, guidelines for the management of hypertension 
have stratified patients according to ethnicity; however, the 
evidence base for the optimum antihypertensive agent for 
each subgroup remains controversial. The CREOLE trial is 
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a multicentre, multinational, randomised study comparing 
three combinations of perindopril, amlodipine and 
hydrochlorthiazide in 700 hypertensive black African adults. 
CREOLE will complete and report in 2019 giving new insight 
into antihypertensive drug choice. 
 BP targets: is higher or lower better? 
 BP targets are controversial; the national and international 
societies are not in agreement as to what is the optimum 
BP target. The results of SPRINT (Systolic Blood Pressure 
Intervention Trial) – published in late 2015 and showing that a 
lower systolic BP target (<120 mmHg) in patients at high risk 
of cardiovascular disease without diabetes is associated with a 
lower risk of fatal and non-fatal cardiovascular events – reignited 
the controversy. 4 Previous studies have shown an association 
between systolic BP <120 mmHg and adverse outcomes, 5,6 while 
a study of 1.25 million people using electronic health records 
reported no J-shaped association. 7 The diastolic BP target is also 
important, with evidence suggesting the presence of a J-shaped 
relationship 8,9 between diastolic BP and adverse outcomes, 
particularly in frail older patients or those with coronary artery 
disease – perhaps a consequence of lowered coronary perfusion 
pressure. 10 
 Measuring blood pressure 
 Approximately one-third of patients with hypertension perform 
home BP monitoring (HBPM). HBPM may be more useful than 
clinic BP for the diagnosis of hypertension, but ambulatory 
BP monitoring (ABPM) remains the gold standard. Elevated BP 
recordings in one or more modality (HBPM, ABPM, clinic BP) 
put the patient at a greater risk of death. 11 HBPM has been used 
with active management in the TASMINH2 study, where patients 
self-titrated antihypertensive agents according to HBPM and 
pre-agreed protocols. There were more medication changes in the 
group who self-managed with 50–70% of patients up-titrating 
per protocol and no associated increase in adverse events. 12 
ABPM has advantages over HBPM in assessing BP variability 
and identifying masked hypertension. Ongoing studies are 
investigating which measurement of BP (24 hour, day or night 
recordings) is the most useful predictor of risk. 
 Hypertension and heart failure 
 The presence of uncontrolled hypertension is strongly 
and independently associated with the development of 
heart failure (HF). Long-term treatment of both systolic and 
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diastolic BP has been shown to reduce the risk of developing 
HF. HF with preserved ejection fraction is common in 
patients with hypertension and there is a non-linear U-shaped 
relationship with increased mortality at the lower and higher 
end of BP control. Drugs that are used to treat hypertension 
also show an independent mortality benefit in HF with 
preserved ejection fraction (beta-blockers, ACEi/ARB). 
Paradoxically, once HF with reduced ejection fraction is 
present, patients with higher systolic BP have better outcomes. 
The population with HF and lower systolic BP (<110 mmHg) 
are at higher risk of hospitalisation for HF and had more severe 
HF than those with systolic BP >120 mmHg. 13 Hypertension 
is associated with the development of atrial fibrillation and 
remains a key part of the risk assessment for anticoagulation in 
stroke prevention. 
 Aldosterone and resistant hypertension 
 At least 5% of patients with hypertension have adrenal 
aldosterone-producing adenomas, which are potentially 
curable with surgery. Aldosterone has adverse cardiovascular 
effects independent of BP. Those with resistant hypertension, 
hypertension in the young or those with low potassium 
(especially with thiazide diuretics) should be screened for 
primary hyperaldosteronism with plasma renin. Further 
investigation may include computerised tomography/magnetic 
resonance imaging adrenal glands followed by adrenal vein 
sampling or, if available,  11 C-metomidate positron emission 
tomography, which has the ability to detect small adenomas 
(<1 cm) often not seen with standard imaging techniques. 
Treatment is with either laproscopic adrenalectomy or 
medical management with spironolactone, eplerenone or 
amiloride. The molecular basis for adrenal aldosterone-
producing adenomas has been studied with mutations found 
in  KCNJ5, ATP1A1 and  CACNA1D giving insight into distinct 
subtypes. 14,15 Primary hyperaldosteronism should no longer be 
thought of as a rarely encountered condition but the diagnosis 
remains highly reliant upon clinical suspicion. 
 Non-adherence to antihypertensive therapy 
 Non-adherence with medication is a common problem in 
chronic diseases and very common in hypertension. Non-
adherence is associated with higher risk of cardiovascular 
events and mortality and a cost to the NHS of >£100 million 
per year. Half of patients thought to have resistant 
hypertension have been found to be completely or partially 
non-adherent. 16 Measures of adherence can take the form of 
traditional patient interviews, pill counts, medication refill 
queries or admission to hospital for directly observed therapy 
and measurement of BP response. High-performance liquid 
chromatography-tandem mass spectrometry analysis of the 
urine gives clinicians and researchers a highly sensitive and 
convenient method to screen for antihypertensive drugs in 
blood or urine samples. These results can allow for detection 
of truly treatment-resistant hypertension or provide a platform 
for open discussion with the non-adherent patient. 
 Salt targets: is low salt better? 
 Average global consumption of salt is 10.2 g/day. The 
Yanomamo Indian tribe of South America continue to consume 
an evolutionary diet containing less than 1 g salt per day and do 
not suffer from hypertension (male average BP 96/61 mmHg) 
or vascular disease. While there is some controversy regarding 
salt intake and cardiovascular disease, there is no evidence that 
a low salt diet increases risk of myocardial infarction or stroke. 
Methods of estimating and measuring dietary salt intake 
in clinical practice and clinical trials are often problematic. 
Reduction in dietary salt leads to a reduction in blood pressure 17 
and cardiovascular risk and is effective across all ethnicities, age 
groups, socio-economic classes and both genders. 18 
 New drugs in hypertension 
 Despite the availability of numerous antihypertensive 
drugs, new drugs with improved safety profiles that have a 
greater effect on BP, are better targeted and better tolerated 
are required. Endothelin (ET) receptor antagonists and 
phosphodiesterase type 5 (PDE5) inhibitors for those with 
resistant hypertension or diabetic nephropathy provided a 
focus of a talk on new drugs in hypertension. ET receptor 
antagonists 19 and PDE5 receptor antagonists 20 have been 
shown to reduce blood pressure and reduce proteinuria and 
show promise as new treatments for hypertension. New drugs 
for hypertension are likely to be directly targeted at high-risk 
groups or indirectly through drug repurposing. 
 Device therapy for hypertension 
 Following the failure of the SIMPLICITY-3 trial to show benefit 
from renal denervation, it was unclear what would be the future 
of device therapy for hypertension. There are ongoing trials 
aiming to improve patient selection for renal denervation and 
improving techniques. Carotid baroreflex activation shows 
promise in reducing blood pressure and trials are ongoing. The 
ROX Coupler device (ROX Medical, San Clemente, CA, USA), 
which creates a conduit ateriovenous anastomosis allowing 
shunt of arterial blood into the venous system, is currently 
being evaluated. 
 Conclusions 
 Hypertension remains a global health epidemic. Conflicting 
evidence surrounding the optimum BP targets presents a 
challenge to the hypertension societies currently revising 
their guidelines. Emerging evidence of the superiority of 
spironolactone over other fourth-line antihypertensive agents 
is likely to feature in upcoming guidelines. Patient adherence 
and lifestyle interventions continue to be challenging. The 
emergence of single pill combinations, new antihypertensive 
agents and device therapy along with the results of the ongoing 
clinical trials in the field of hypertension will be of great interest 
in the near future. ■ 
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